ストックスクリーナーアプリを入手
33.05
4.45%
-1.54
アフターアワーズ：
32.63
-0.42
-1.27%
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
New York State Teachers Retirement System Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus plunges as mid-stage trial for depression therapy fails - MSN
Supernus' depression treatment fails mid-stage trial, shares plunge - MSN
Depression failure sends Supernus shares downwards - The Pharma Letter
How the (SUPN) price action is used to our Advantage - Stock Traders Daily
Supernus phase IIb results drag down the stock - BioWorld Online
Cantor Fitzgerald cuts Supernus stock rating, target to $36 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial - AOL
Supernus’s stock sinks after depression drug fails trial - Yahoo
Sanofi reaches consumer health deal; Supernus antidepressant fails study - BioPharma Dive
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & ... - The Bakersfield Californian
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; - GlobeNewswire
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsSUPN - ACCESS Newswire
Supernus stock falls after trial setback (update) (SUPN:NASDAQ) - Seeking Alpha
Supernus reports less than super data for depression drug - pharmaphorum
Supernus Plunges On Failed Phase 2b Study Of SPN-820 In Treatment-resistant Depression - Nasdaq
Supernus Pharma sinks after depression drug fails mid-stage trial goal - TradingView
Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint - Marketscreener.com
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression - GlobeNewswire
Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression - Marketscreener.com
Supernus' depression treatment fails mid-stage trial, shares plunge -February 18, 2025 at 04:49 pm EST - Marketscreener.com
Supernus' depression treatment fails mid-stage trial -February 18, 2025 at 04:35 pm EST - Marketscreener.com
Supernus Pharma stock tumbles after failed depression study By Investing.com - Investing.com Nigeria
Supernus Pharma stock tumbles after failed depression study - Investing.com India
Clinical Trial Setback: Supernus Depression Treatment Shows No Advantage Over Placebo - StockTitan
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57 - Marketscreener.com
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Yousif Capital Management LLC Sells 425 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Armenian Reporter
41,426 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Empowered Funds LLC - Defense World
Yousif Capital Management LLC Has $768,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Access to Parkinson’s medication likely by summer: Supernus official - Parkinson's News Today
Janney Montgomery Scott LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stephens Investment Management Group LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Q4 Earnings: CEO and CFO Set to Unveil Full Year Performance Metrics - StockTitan
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking - Simply Wall St
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells 9,477 Shares of Stock - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year HighHere's Why - MarketBeat
Supernus wins FDA approval for Parkinson’s pump on fourth try - MSN
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight - The Globe and Mail
Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha
US FDA approves Supernus' drug-device combination for Parkinson's disease - MSN
Top Supernus Executive Offloads Significant Stock Holdings! - TipRanks
Supernus Pharmaceuticals exec sells shares worth $376,236 By Investing.com - Investing.com Australia
Supernus Pharmaceuticals exec sells shares worth $376,236 - MSN
FDA nod at last for Supernus’ Parkinson’s infusion therapy - The Pharma Letter
Stifel maintains hold on Supernus, price target at $38 - MSN
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire
Supernus stock climbs 5% on FDA approval of Onapgo - MSN
Supernus Pharmaceuticals Inc [SUPN] Stock sold by Insider Bhatt Padmanabh P. for $0.1 million - Knox Daily
Supernus stock price target raised to $44 at TD Cowen - MSN
Supernus stock price target raised to $44 at TD Cowen By Investing.com - Investing.com Canada
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):